AstraZeneca PLC (AZN) 10-Year Financial Performance & Capital Metrics

AZN • • Industrial / General

HealthcareLarge PharmaBroad-Based Pharmaceutical GiantsGlobal Pharma Diversified Leaders

AboutAstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.Show more

Revenue $54.07B +18.0%
EBITDA $15.07B +14.8%
Net Income $7.04B +18.1%
EPS (Diluted) 1.13 -40.8%
Gross Margin 81.12% -1.0%
EBITDA Margin 27.87% -2.8%
Operating Margin 18.5% +3.4%
Net Margin 13.01%
ROE 17.58% +12.5%
ROIC 11.77% +16.9%
Debt/Equity 0.74 +0.8%
Interest Coverage 5.95 +15.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y profit CAGR of 39.4%
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 17.3%
✓Trading near 52-week high

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y7.37%

5Y17.27%

3Y13.06%

TTM13.52%

Profit (Net Income) CAGR

10Y19.02%

5Y39.43%

3Y297.51%

TTM44.71%

EPS CAGR

10Y8.71%

5Y16.79%

3Y204.56%

TTM44.5%

ROCE

10Y Avg8.53%

5Y Avg8.67%

3Y Avg10.06%

Latest13.63%

Peer Comparison

Global Pharma Diversified Leaders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AZNAstraZeneca PLC	293.03B	94.51	83.64	18.04%	16.17%	20.45%	2.48%	0.74
GSKGSK plc	100.65B	49.90	40.24	3.46%	17.08%	25.91%	3.55%	1.30
JNJJohnson & Johnson	514.75B	213.65	36.90	4.3%	27.26%	31.69%	3.85%	0.53
NVSNovartis AG	271.72B	141.61	24.12	10.85%	25.53%	32.16%	5.08%	0.71
SNYSanofi	114.36B	47.20	21.55	6.41%	21.16%	12.99%	5.15%	0.23
PFEPfizer Inc.	143B	25.15	17.84	6.84%	15.64%	10.55%	6.88%	0.76
MRKMerck & Co., Inc.	268.7B	108.26	16.06	6.74%	29.63%	36.67%	6.73%	0.83

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	24.71B	23B	22.46B	22.09B	24.38B	26.62B	37.42B	44.35B	45.81B	54.07B
Revenue Growth %	-0.07%	-0.07%	-0.02%	-0.02%	0.1%	0.09%	0.41%	0.19%	0.03%	0.18%
Cost of Goods Sold+	4.65B	4.13B	4.32B	4.94B	4.92B	5.3B	12.44B	12.39B	8.27B	10.21B
COGS % of Revenue	0.19%	0.18%	0.19%	0.22%	0.2%	0.2%	0.33%	0.28%	0.18%	0.19%
Gross Profit+	20.06B	18.88B	18.15B	17.15B	19.46B	21.32B	24.98B	31.96B	37.54B	43.87B
Gross Margin %	0.81%	0.82%	0.81%	0.78%	0.8%	0.8%	0.67%	0.72%	0.82%	0.81%
Gross Profit Growth %	-0.03%	-0.06%	-0.04%	-0.05%	0.13%	0.1%	0.17%	0.28%	0.17%	0.17%
Operating Expenses+	15.95B	13.97B	14.47B	13.77B	16.54B	16.16B	23.92B	28.2B	29.35B	33.86B
OpEx % of Revenue	0.65%	0.61%	0.64%	0.62%	0.68%	0.61%	0.64%	0.64%	0.64%	0.63%
Selling, General & Admin	11.52B	9.74B	10.54B	10.98B	11.98B	11.9B	15.59B	17.98B	18.22B	20.22B
SG&A % of Revenue	0.47%	0.42%	0.47%	0.5%	0.49%	0.45%	0.42%	0.41%	0.4%	0.37%
Research & Development	6B	5.89B	5.76B	5.93B	6.06B	5.99B	9.74B	9.76B	10.94B	13.58B
R&D % of Revenue	0.24%	0.26%	0.26%	0.27%	0.25%	0.23%	0.26%	0.22%	0.24%	0.25%
Other Operating Expenses	-1.56B	-1.66B	-1.83B	-3.15B	-1.5B	-1.73B	-1.4B	457M	193M	56M
Operating Income+	4.11B	4.9B	3.68B	3.39B	2.92B	5.16B	1.06B	3.76B	8.19B	10B
Operating Margin %	0.17%	0.21%	0.16%	0.15%	0.12%	0.19%	0.03%	0.08%	0.18%	0.18%
Operating Income Growth %	0.93%	0.19%	-0.25%	-0.08%	-0.14%	0.77%	-0.8%	2.56%	1.18%	0.22%
EBITDA+	6.97B	7.26B	6.71B	7.14B	6.69B	8.06B	5.16B	9.01B	13.13B	15.07B
EBITDA Margin %	0.28%	0.32%	0.3%	0.32%	0.27%	0.3%	0.14%	0.2%	0.29%	0.28%
EBITDA Growth %	0.29%	0.04%	-0.08%	0.06%	-0.06%	0.21%	-0.36%	0.75%	0.46%	0.15%
D&A (Non-Cash Add-back)	2.85B	2.36B	3.04B	3.75B	3.76B	2.9B	4.1B	5.25B	4.93B	5.07B
EBIT	4.11B	4.92B	3.59B	3.36B	2.95B	5.19B	1.01B	3.83B	8.49B	10.37B
Net Interest Income+	-1B	-1.31B	-1.25B	-1.23B	-1.24B	-1.19B	-1.23B	-1.25B	-1.29B	-1.34B
Interest Income	36M	59M	109M	138M	165M	83M	43M	81M	301M	345M
Interest Expense	1.04B	1.37B	1.36B	1.37B	1.4B	1.27B	1.28B	1.33B	1.59B	1.68B
Other Income/Expense	-1.04B	-1.35B	-1.45B	-1.39B	-1.38B	-1.25B	-1.32B	-1.26B	-1.29B	-1.31B
Pretax Income+	3.07B	3.55B	2.23B	1.99B	1.55B	3.92B	-265M	2.5B	6.9B	8.69B
Pretax Margin %	0.12%	0.15%	0.1%	0.09%	0.06%	0.15%	-0.01%	0.06%	0.15%	0.16%
Income Tax+	243M	146M	-641M	-57M	321M	772M	-380M	-792M	938M	1.65B
Effective Tax Rate %	0.92%	0.99%	1.35%	1.08%	0.86%	0.82%	-0.42%	1.31%	0.86%	0.81%
Net Income+	2.83B	3.5B	3B	2.15B	1.33B	3.2B	112M	3.29B	5.96B	7.04B
Net Margin %	0.11%	0.15%	0.13%	0.1%	0.05%	0.12%	0%	0.07%	0.13%	0.13%
Net Income Growth %	1.29%	0.24%	-0.14%	-0.28%	-0.38%	1.39%	-0.96%	28.36%	0.81%	0.18%
Net Income (Continuing)	2.83B	3.41B	2.87B	2.05B	1.23B	3.14B	115M	3.29B	5.96B	7.04B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	19M	1.81B	1.68B	1.58B	1.47B	16M	19M	21M	23M	85M
EPS (Diluted)+	1.12	1.38	1.19	0.85	0.52	1.22	0.04	1.06	1.91	1.13
EPS Growth %	1.29%	0.23%	-0.14%	-0.29%	-0.39%	1.35%	-0.97%	25.5%	0.8%	-0.41%
EPS (Basic)	1.12	1.39	1.19	0.85	0.52	1.22	0.04	1.06	1.91	1.14
Diluted Shares Outstanding	2.53B	2.53B	2.53B	2.53B	2.6B	2.63B	2.85B	3.12B	3.12B	3.13B
Basic Shares Outstanding	2.53B	2.53B	2.53B	2.53B	2.6B	2.62B	2.84B	3.1B	3.12B	3.1B
Dividend Payout Ratio	1.23%	1.02%	1.17%	1.62%	2.69%	1.12%	34.43%	1.33%	0.75%	0.66%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	16.01B	13.26B	13.15B	15.59B	15.56B	19.54B	26.24B	22.59B	25.05B	25.83B
Cash & Short-Term Investments	6.85B	5.9B	4.55B	5.68B	6.22B	7.99B	6.4B	6.24B	5.86B	5.53B
Cash Only	6.24B	5.02B	3.32B	4.83B	5.37B	7.83B	6.33B	6.17B	5.84B	5.49B
Short-Term Investments	613M	884M	1.23B	849M	849M	160M	69M	77M	20M	37M
Accounts Receivable	4.63B	2.58B	2.8B	3B	4.9B	5.65B	8.13B	9.19B	8.41B	11.23B
Days Sales Outstanding	68.44	40.99	45.53	49.49	73.29	77.49	79.33	75.65	66.98	75.84
Inventory	2.14B	2.33B	3.04B	2.89B	3.19B	4.02B	8.98B	4.7B	5.42B	5.29B
Days Inventory Outstanding	168.36	206.47	256.55	213.71	236.83	277.18	263.63	138.42	239.45	189.1
Other Current Assets	2.23B	2.31B	1.68B	3.08B	392M	142M	1.22B	1.13B	3.75B	2.04B
Total Non-Current Assets+	44.12B	49.26B	50.2B	45.06B	45.81B	47.19B	79.12B	73.89B	76.06B	78.21B
Property, Plant & Equipment	6.41B	6.85B	7.62B	7.42B	8.34B	8.92B	10.17B	9.45B	10.5B	11.65B
Fixed Asset Turnover	3.85x	3.36x	2.95x	2.98x	2.93x	2.98x	3.68x	4.69x	4.36x	4.64x
Goodwill	11.87B	11.66B	11.82B	11.71B	11.67B	11.85B	20B	19.82B	20.05B	21.02B
Intangible Assets	22.65B	27.59B	26.19B	21.96B	20.83B	20.95B	42.39B	39.31B	38.09B	37.18B
Long-Term Investments	-70M	-58M	-194M	113M	0	0	0	0	1.78B	0
Other Non-Current Assets	1.97B	2.13B	2.58B	1.48B	2.26B	2.04B	2.23B	2.05B	5.65B	3.01B
Total Assets+	60.12B	62.53B	63.35B	60.65B	61.38B	66.73B	105.36B	96.48B	101.12B	104.03B
Asset Turnover	0.41x	0.37x	0.35x	0.36x	0.40x	0.40x	0.36x	0.46x	0.45x	0.52x
Asset Growth %	0.03%	0.04%	0.01%	-0.04%	0.01%	0.09%	0.58%	-0.08%	0.05%	0.03%
Total Current Liabilities+	14.87B	15.26B	16.38B	16.29B	18.12B	20.31B	22.59B	26.29B	30.54B	27.87B
Accounts Payable	3.47B	1.68B	2.29B	1.72B	1.77B	2.35B	2.82B	2.55B	3.27B	3.64B
Days Payables Outstanding	272.53	148.62	193.15	127.19	131.58	161.87	82.88	75.11	144.23	130.17
Short-Term Debt	858M	2.24B	2.27B	1.78B	1.82B	2.19B	1.57B	5.22B	5.13B	2.16B
Deferred Revenue (Current)	-1000K	-1000K	-1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	3.98B	4B	4.21B	3.73B	9.96B	12.27B	14.94B	15B	6.13B	17.31B
Current Ratio	1.08x	0.87x	0.80x	0.96x	0.86x	0.96x	1.16x	0.86x	0.82x	0.93x
Quick Ratio	0.93x	0.72x	0.62x	0.78x	0.68x	0.76x	0.76x	0.68x	0.64x	0.74x
Cash Conversion Cycle	-35.73	98.84	108.92	136	178.54	192.8	260.08	138.95	162.21	134.77
Total Non-Current Liabilities+	26.75B	30.6B	30.33B	30.32B	28.66B	30.78B	43.48B	33.13B	31.41B	35.3B
Long-Term Debt	14.11B	16.51B	17.39B	19.2B	15.73B	17.5B	28.13B	22.96B	22.36B	26.51B
Capital Lease Obligations	28M	6M	0	0	487M	489M	754M	725M	857M	1.11B
Deferred Tax Liabilities	2.73B	3.96B	4B	3.29B	2.49B	2.92B	6.21B	2.94B	31M	3.31B
Other Non-Current Liabilities	12.61B	14.08B	12.94B	11.11B	9.91B	9.83B	8.36B	6.48B	8.15B	4.37B
Total Liabilities	41.62B	45.86B	46.71B	46.61B	46.78B	51.09B	66.08B	59.42B	61.95B	63.16B
Total Debt+	15.05B	16.81B	17.81B	19.11B	18.23B	20.38B	30.69B	29.14B	28.62B	30.11B
Net Debt	8.81B	11.79B	14.48B	14.28B	12.86B	12.55B	24.36B	22.98B	22.78B	24.63B
Debt / Equity	0.81x	1.01x	1.07x	1.36x	1.25x	1.30x	0.78x	0.79x	0.73x	0.74x
Debt / EBITDA	2.16x	2.32x	2.65x	2.68x	2.73x	2.53x	5.95x	3.23x	2.18x	2.00x
Net Debt / EBITDA	1.27x	1.62x	2.16x	2.00x	1.92x	1.56x	4.72x	2.55x	1.74x	1.63x
Interest Coverage	3.96x	3.59x	2.70x	2.48x	2.09x	4.06x	0.83x	2.82x	5.16x	5.95x
Total Equity+	18.51B	16.67B	16.64B	14.04B	14.6B	15.64B	39.29B	37.06B	39.17B	40.87B
Equity Growth %	-0.06%	-0.1%	-0%	-0.16%	0.04%	0.07%	1.51%	-0.06%	0.06%	0.04%
Book Value per Share	7.32	6.58	6.57	5.54	5.61	5.96	13.77	11.88	12.54	13.07
Total Shareholders' Equity	18.49B	14.85B	14.96B	12.47B	13.13B	15.62B	39.27B	37.04B	39.14B	40.79B
Common Stock	316M	316M	317M	317M	328M	328M	387M	387M	388M	388M
Retained Earnings	11.83B	8.14B	8.22B	5.68B	2.81B	5.3B	1.71B	-574M	4.52B	3.16B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1.66B	99M	1.01B	34M	0	0	0	0	0	0
Minority Interest	19M	1.81B	1.68B	1.58B	1.47B	16M	19M	21M	23M	85M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	3.32B	4.14B	3.58B	2.62B	2.97B	4.8B	5.96B	9.81B	10.35B	11.86B
Operating CF Margin %	0.13%	0.18%	0.16%	0.12%	0.12%	0.18%	0.16%	0.22%	0.23%	0.22%
Operating CF Growth %	-0.53%	0.25%	-0.14%	-0.27%	0.13%	0.62%	0.24%	0.64%	0.05%	0.15%
Net Income	3.07B	3.55B	2.23B	1.99B	1.55B	3.92B	-265M	2.5B	6.9B	8.69B
Depreciation & Amortization	2.85B	2.36B	3.04B	3.75B	3.76B	3.15B	6.53B	5.48B	4.93B	5.07B
Stock-Based Compensation	0	0	0	0	259M	277M	615M	619M	579M	0
Deferred Taxes	0	0	0	0	-259M	-277M	-615M	-619M	0	0
Other Non-Cash Items	-2.55B	-2.69B	-1.64B	-2.49B	-2B	-2.63B	-2.32B	-1.93B	-2.37B	-1B
Working Capital Changes	-49M	926M	-50M	-639M	-346M	361M	2.02B	3.76B	300M	-893M
Change in Receivables	152M	1.61B	83M	-523M	-898M	-739M	-961M	-1.35B	-1.43B	-1.62B
Change in Inventory	-315M	-343M	-548M	-13M	-316M	-621M	1.58B	3.94B	-669M	-131M
Change in Payables	0	0	0	0	898M	739M	961M	1.35B	1.43B	0
Cash from Investing+	-4.24B	-3.97B	-2.33B	963M	-657M	-285M	-11.06B	-2.96B	-4.06B	-7.98B
Capital Expenditures	-2.79B	-2.31B	-1.62B	-1.37B	-2.46B	-2.61B	-2.2B	-2.57B	-1.36B	-1.92B
CapEx % of Revenue	0.11%	0.1%	0.07%	0.06%	0.1%	0.1%	0.06%	0.06%	0.03%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	1.3B	1.64B	1.62B	2.54B	2.39B	1.14B	654M	789M	-1.52B	-2.14B
Cash from Financing+	878M	-1.32B	-2.94B	-2.04B	-1.76B	-2.2B	3.65B	-6.82B	-6.57B	-4B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-3.49B	-3.56B	-3.52B	-3.48B	-3.59B	-3.57B	-3.86B	-4.36B	-4.48B	-4.63B
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-93M	-285M	316M	-33M	3.01B	-308M	-418M	-1.29B	-1.15B	-1.13B
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	536M	1.83B	1.96B	1.25B	509M	2.19B	3.76B	7.24B	6.57B	7.28B
FCF Margin %	0.02%	0.08%	0.09%	0.06%	0.02%	0.08%	0.1%	0.16%	0.14%	0.13%
FCF Growth %	-0.88%	2.42%	0.07%	-0.36%	-0.59%	3.31%	0.72%	0.92%	-0.09%	0.11%
FCF per Share	0.21	0.72	0.77	0.49	0.20	0.84	1.32	2.32	2.10	2.33
FCF Conversion (FCF/Net Income)	1.18x	1.18x	1.19x	1.21x	2.22x	1.50x	53.24x	2.98x	1.74x	1.69x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	14.81%	19.89%	18.02%	14.05%	9.32%	21.14%	0.41%	8.61%	15.63%	17.58%
Return on Invested Capital (ROIC)	11.99%	13.18%	9.26%	8.55%	7.86%	13.92%	1.72%	4.56%	10.07%	11.77%
Gross Margin	81.2%	82.06%	80.78%	77.66%	79.82%	80.09%	66.76%	72.06%	81.95%	81.12%
Net Margin	11.43%	15.21%	13.36%	9.76%	5.47%	12.01%	0.3%	7.41%	13%	13.01%
Debt / Equity	0.81x	1.01x	1.07x	1.36x	1.25x	1.30x	0.78x	0.79x	0.73x	0.74x
Interest Coverage	3.96x	3.59x	2.70x	2.48x	2.09x	4.06x	0.83x	2.82x	5.16x	5.95x
FCF Conversion	1.18x	1.18x	1.19x	1.21x	2.22x	1.50x	53.24x	2.98x	1.74x	1.69x
Revenue Growth	-6.93%	-6.9%	-2.33%	-1.67%	10.38%	9.16%	40.58%	18.53%	3.29%	18.04%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023
Total Oncology	-	-	-	-	-	14.63B	17.14B
Total Oncology Growth	-	-	-	-	-	-	17.18%
CVRM	-	-	-	-	-	9.19B	10.59B
CVRM Growth	-	-	-	-	-	-	15.20%
Rare Disease	-	-	-	-	-	7.05B	7.76B
Rare Disease Growth	-	-	-	-	-	-	10.08%
Farxiga	1.07B	1.39B	1.54B	-	-	4.38B	5.96B
Farxiga Growth	-	29.52%	10.93%	-	-	-	36.11%
Tagrisso	955M	1.86B	3.19B	-	-	5.44B	5.8B
Tagrisso Growth	-	94.76%	71.45%	-	-	-	6.52%
Imfinzi	-	633M	1.47B	-	-	2.78B	4.24B
Imfinzi Growth	-	-	132.07%	-	-	-	52.19%
Soliris	-	-	-	-	-	3.76B	3.15B
Soliris Growth	-	-	-	-	-	-	-16.40%
Ultomiris.	-	-	-	-	-	1.97B	2.96B
Ultomiris. Growth	-	-	-	-	-	-	50.89%
Lynparza	297M	647M	1.2B	-	-	2.64B	2.81B
Lynparza Growth	-	117.85%	85.16%	-	-	-	6.56%
Calquence	-	62M	164M	-	-	2.06B	2.51B
Calquence Growth	-	-	164.52%	-	-	-	22.22%
Symbicort	2.8B	2.56B	2.5B	-	-	2.54B	2.36B
Symbicort Growth	-	-8.63%	-2.58%	-	-	-	-6.93%
Fasenra	-	297M	704M	-	-	1.4B	1.55B
Fasenra Growth	-	-	137.04%	-	-	-	11.25%
Brilinta	1.08B	1.32B	1.58B	-	-	1.36B	1.32B
Brilinta Growth	-	22.43%	19.68%	-	-	-	-2.50%
Total Other medicines	-	-	-	-	-	1.63B	1.18B
Total Other medicines Growth	-	-	-	-	-	-	-27.63%
Strensiq	-	-	-	-	-	958M	1.15B
Strensiq Growth	-	-	-	-	-	-	20.25%
Crestor	2.37B	1.43B	1.28B	1.18B	1.1B	1.05B	1.11B
Crestor Growth	-	-39.41%	-10.82%	-7.67%	-7.12%	-4.38%	5.63%
Enhertu	-	-	-	-	17M	79M	1.02B
Enhertu Growth	-	-	-	-	-	364.71%	1193.67%
Zoladex	735M	752M	813M	888M	948M	927M	952M
Zoladex Growth	-	2.31%	8.11%	9.23%	6.76%	-2.22%	2.70%
Nexium	1.95B	1.7B	1.48B	-	1.33B	1.28B	945M
Nexium Growth	-	-12.81%	-12.87%	-	-	-3.09%	-26.46%
Pulmicort	1.18B	1.29B	1.47B	-	-	645M	713M
Pulmicort Growth	-	9.35%	14.00%	-	-	-	10.54%
Breztri	-	-	2M	-	-	398M	677M
Breztri Growth	-	-	-	-	-	-	70.10%
Seloken/Toprol-XL	-	-	-	-	-	862M	640M
Seloken/Toprol-XL Growth	-	-	-	-	-	-	-25.75%
Synagis	687M	665M	358M	-	-	578M	546M
Synagis Growth	-	-3.20%	-46.17%	-	-	-	-5.54%
Lokelma	-	-	14M	-	-	289M	412M
Lokelma Growth	-	-	-	-	-	-	42.56%
Koselugo	-	-	-	-	-	208M	331M
Koselugo Growth	-	-	-	-	-	-	59.13%
Faslodex	941M	1.03B	892M	-	-	334M	297M
Faslodex Growth	-	9.25%	-13.23%	-	-	-	-11.08%
Saphnelo	-	-	-	-	-	116M	280M
Saphnelo Growth	-	-	-	-	-	-	141.38%
Roxadustat	-	-	-	-	174M	197M	271M
Roxadustat Growth	-	-	-	-	-	13.22%	37.56%
Other, Others	-	-	-	-	-	340M	231M
Other, Others Growth	-	-	-	-	-	-	-32.06%
Onglyza	611M	543M	527M	-	-	257M	227M
Onglyza Growth	-	-11.13%	-2.95%	-	-	-	-11.67%
Oncology, Others	-	-	-	-	-	44M	224M
Oncology, Others Growth	-	-	-	-	-	-	409.09%
FluMist	-	-	-	-	-	175M	216M
FluMist Growth	-	-	-	-	-	-	23.43%
Andexxa	-	-	-	-	-	150M	182M
Andexxa Growth	-	-	-	-	-	-	21.33%
Kanuma	-	-	-	-	-	160M	171M
Kanuma Growth	-	-	-	-	-	-	6.88%
Bydureon	574M	584M	549M	-	-	280M	163M
Bydureon Growth	-	1.74%	-5.99%	-	-	-	-41.79%
Bevespi	-	33M	42M	-	-	58M	58M
Bevespi Growth	-	-	27.27%	-	-	-	0.00%
Daliresp/Daxas	-	-	-	-	-	189M	54M
Daliresp/Daxas Growth	-	-	-	-	-	-	-71.43%
Vaxzevria	-	-	-	-	-	1.8B	12M
Vaxzevria Growth	-	-	-	-	-	-	-99.33%
BioPharmaceuticals: total Respiratory & Immunology	-	-	-	-	-	5.76B	-
BioPharmaceuticals: total Respiratory & Immunology Growth	-	-	-	-	-	-	-
Respiratory, Others	-	-	-	-	-	421M	-
Respiratory, Others Growth	-	-	-	-	-	-	-
Iressa	528M	518M	423M	-	-	114M	-
Iressa Growth	-	-1.89%	-18.34%	-	-	-	-
Arimidex	217M	212M	225M	-	-	99M	-
Arimidex Growth	-	-2.30%	6.13%	-	-	-	-
Casodex	215M	201M	200M	-	-	78M	-
Casodex Growth	-	-6.51%	-0.50%	-	-	-	-
Ophatys	-	-	-	-	-	33M	-
Ophatys Growth	-	-	-	-	-	-	-
Lynparza/Koselugo	-	-	-	-	400M	-	-
Lynparza/Koselugo Growth	-	-	-	-	-	-	-
Profit share revenue from product sales by collaboration partners	-	-	-	-	200M	-	-
Profit share revenue from product sales by collaboration partners Growth	-	-	-	-	-	-	-
Royal income	-	-	-	-	138M	-	-
Royal income Growth	-	-	-	-	-	-	-
Other Ongoing Collaboration Revenue	-	-	-	-	64M	-	-
Other Ongoing Collaboration Revenue Growth	-	-	-	-	-	-	-
Collaboration Revenue	-	-	-	-	12M	-	-
Collaboration Revenue Growth	-	-	-	-	-	-	-
Lynparza And Koselugo	-	-	-	460M	-	-	-
Lynparza And Koselugo Growth	-	-	-	-	-	-	-
Royal Revenue	-	-	-	62M	-	-	-
Royal Revenue Growth	-	-	-	-	-	-	-
Other Collaboration Revenue	-	-	-	46M	-	-	-
Other Collaboration Revenue Growth	-	-	-	-	-	-	-
Oncology Products	4.02B	6.03B	8.67B	-	-	-	-
Oncology Products Growth	-	49.80%	43.78%	-	-	-	-
Cardiovascular And Metabolic Diseases Products	7.27B	6.71B	6.91B	-	-	-	-
Cardiovascular And Metabolic Diseases Products Growth	-	-7.65%	2.92%	-	-	-	-
Respiratory Products	4.71B	4.91B	5.39B	-	-	-	-
Respiratory Products Growth	-	4.36%	9.77%	-	-	-	-
Other Products	4.16B	3.4B	2.6B	-	-	-	-
Other Products Growth	-	-18.19%	-23.50%	-	-	-	-
Seloken Toprol Xl	695M	712M	760M	-	-	-	-
Seloken Toprol Xl Growth	-	2.45%	6.74%	-	-	-	-
Other Respiratory Products	379M	340M	390M	-	-	-	-
Other Respiratory Products Growth	-	-10.29%	14.71%	-	-	-	-
Other Products Others	206M	181M	306M	-	-	-	-
Other Products Others Growth	-	-12.14%	69.06%	-	-	-	-
Other Cardiovascular And Metabolic Diseases Products	282M	306M	271M	-	-	-	-
Other Cardiovascular And Metabolic Diseases Products Growth	-	8.51%	-11.44%	-	-	-	-
Losec Prilosec	271M	272M	263M	-	-	-	-
Losec Prilosec Growth	-	0.37%	-3.31%	-	-	-	-
Atacand	300M	260M	221M	-	-	-	-
Atacand Growth	-	-13.33%	-15.00%	-	-	-	-
Daliresp Daxas	198M	189M	215M	-	-	-	-
Daliresp Daxas Growth	-	-4.55%	13.76%	-	-	-	-
Seroquel Xr Ir	-	361M	191M	-	-	-	-
Seroquel Xr Ir Growth	-	-	-47.09%	-	-	-	-
Byetta	176M	126M	110M	-	-	-	-
Byetta Growth	-	-28.41%	-12.70%	-	-	-	-
Other Oncology Products	136M	115M	94M	-	-	-	-
Other Oncology Products Growth	-	-15.44%	-18.26%	-	-	-	-
Duaklir	-	95M	77M	-	-	-	-
Duaklir Growth	-	-	-18.95%	-	-	-	-
Other Diabetes	-	-	52M	-	-	-	-
Other Diabetes Growth	-	-	-	-	-	-	-
Tudorza Eklira	150M	110M	-	-	-	-	-
Tudorza Eklira Growth	-	-26.67%	-	-	-	-	-
Flumist Fluenz	78M	110M	-	-	-	-	-
Flumist Fluenz Growth	-	41.03%	-	-	-	-	-
Movantik Moventig	-	109M	-	-	-	-	-
Movantik Moventig Growth	-	-	-	-	-	-	-
Symlin	-	34M	-	-	-	-	-
Symlin Growth	-	-	-	-	-	-	-
Lynparza And Selumetinb	1.25B	-	-	-	-	-	-
Lynparza And Selumetinb Growth	-	-	-	-	-	-	-
Seroquel Xr	332M	-	-	-	-	-	-
Seroquel Xr Growth	-	-	-	-	-	-	-
Local Anaesthetics	228M	-	-	-	-	-	-
Local Anaesthetics Growth	-	-	-	-	-	-	-
Seroquel Ir	179M	-	-	-	-	-	-
Seroquel Ir Growth	-	-	-	-	-	-	-
Movantik	122M	-	-	-	-	-	-
Movantik Growth	-	-	-	-	-	-	-
Plendil	110M	-	-	-	-	-	-
Plendil Growth	-	-	-	-	-	-	-
Diprivan	64M	-	-	-	-	-	-
Diprivan Growth	-	-	-	-	-	-	-
Merrem	37M	-	-	-	-	-	-
Merrem Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

AstraZeneca PLC (AZN) has a price-to-earnings (P/E) ratio of 83.6x. This suggests investors expect higher future growth.

Growth & Financials

AstraZeneca PLC (AZN) reported $58.13B in revenue for fiscal year 2024. This represents a 73% increase from $33.59B in 2011.

AstraZeneca PLC (AZN) grew revenue by 18.0% over the past year. This is strong growth.

Yes, AstraZeneca PLC (AZN) is profitable, generating $9.40B in net income for fiscal year 2024 (13.0% net margin).

Dividend & Returns

Yes, AstraZeneca PLC (AZN) pays a dividend with a yield of 1.57%. This makes it attractive for income-focused investors.

AstraZeneca PLC (AZN) has a return on equity (ROE) of 17.6%. This is reasonable for most industries.

AstraZeneca PLC (AZN) generated $11.15B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...